Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study
(1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal c...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/8/2400 |
| _version_ | 1797561181353803776 |
|---|---|
| author | Marie Selvy Bruno Pereira Nicolas Kerckhove Coralie Gonneau Gabrielle Feydel Caroline Pétorin Agnès Vimal-Baguet Sergey Melnikov Sharif Kullab Mohamed Hebbar Olivier Bouché Florian Slimano Vincent Bourgeois Valérie Lebrun-Ly Frédéric Thuillier Thibault Mazard David Tavan Kheir Eddine Benmammar Brigitte Monange Mohamed Ramdani Denis Péré-Vergé Floriane Huet-Penz Ahmed Bedjaoui Florent Genty Cécile Leyronnas Jérôme Busserolles Sophie Trevis Vincent Pinon Denis Pezet David Balayssac |
| author_facet | Marie Selvy Bruno Pereira Nicolas Kerckhove Coralie Gonneau Gabrielle Feydel Caroline Pétorin Agnès Vimal-Baguet Sergey Melnikov Sharif Kullab Mohamed Hebbar Olivier Bouché Florian Slimano Vincent Bourgeois Valérie Lebrun-Ly Frédéric Thuillier Thibault Mazard David Tavan Kheir Eddine Benmammar Brigitte Monange Mohamed Ramdani Denis Péré-Vergé Floriane Huet-Penz Ahmed Bedjaoui Florent Genty Cécile Leyronnas Jérôme Busserolles Sophie Trevis Vincent Pinon Denis Pezet David Balayssac |
| author_sort | Marie Selvy |
| collection | DOAJ |
| description | (1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal cancer. (2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess the prevalence of CIPN, as well as its consequences (neuropathic pain, anxiety, depression, and quality of life) in cancer survivors during the 5 years after the end of adjuvant oxaliplatin chemotherapy. (3) Results: Out of 406 patients, the prevalence of CIPN was 31.3% (95% confidence interval: 26.8–36.0). Little improvement in CIPN was found over the 5 years, and 36.5% of patients with CIPN also had neuropathic pain. CIPN was associated with anxiety, depression, and deterioration of quality of life. None of the patients with CIPN were treated with duloxetine (recommendation from American Society of Clinical Oncology), and only 3.2%, 1.6%, and 1.6% were treated with pregabalin, gabapentin, and amitriptyline, respectively. (4) Conclusions: Five years after the end of chemotherapy, a quarter of patients suffered from CIPN. The present study showed marked psychological distress and uncovered a failure in management in these patients. |
| first_indexed | 2024-03-10T18:11:27Z |
| format | Article |
| id | doaj.art-ca6c3c67ca404ed387926f52da7f3bc0 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T18:11:27Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-ca6c3c67ca404ed387926f52da7f3bc02023-11-20T08:07:18ZengMDPI AGJournal of Clinical Medicine2077-03832020-07-0198240010.3390/jcm9082400Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional StudyMarie Selvy0Bruno Pereira1Nicolas Kerckhove2Coralie Gonneau3Gabrielle Feydel4Caroline Pétorin5Agnès Vimal-Baguet6Sergey Melnikov7Sharif Kullab8Mohamed Hebbar9Olivier Bouché10Florian Slimano11Vincent Bourgeois12Valérie Lebrun-Ly13Frédéric Thuillier14Thibault Mazard15David Tavan16Kheir Eddine Benmammar17Brigitte Monange18Mohamed Ramdani19Denis Péré-Vergé20Floriane Huet-Penz21Ahmed Bedjaoui22Florent Genty23Cécile Leyronnas24Jérôme Busserolles25Sophie Trevis26Vincent Pinon27Denis Pezet28David Balayssac29INSERM U1107 NEURO-DOL, Université Clermont Auvergne, F-63000 Clermont-Ferrand, FranceDélégation à la Recherche Clinique et à l’Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, F-63000 Clermont-Ferrand, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, F-63000 Clermont-Ferrand, FranceDélégation à la Recherche Clinique et à l’Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, FranceService de Chirurgie digestive, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, FranceService de Chirurgie digestive, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, FranceCentre Hospitalier de Saint-Flour, Service Chirurgie générale et viscérale, F-15100 Saint-Flour, FranceCentre Hospitalier de Moulins Yzeure, Service Oncologie, F-03006 Moulins, FranceCHRU Lille, Service Oncologie, F-59000 Lille, FranceCHU Reims, Service Oncologie digestive, Université de Reims Champagne-Ardenne, F-51100 Reims, FranceCHU Reims, Service Pharmacie, BioSpecT, EA n 7506, SFR CAP-Santé, Université de Reims Champagne-Ardenne, F-51100 Reims, FranceCentre Hospitalier de Boulogne sur Mer, Service Oncologie digestive, F-62321 Boulogne-Sur-Mer, FranceCHU Limoges, Service Oncologie, F-87042 Limoges, FranceCHU Limoges, Service Oncologie, F-87042 Limoges, FranceIRCM, Inserm, Univ Montpellier, ICM, F-34298 Montpellier, FranceInfirmerie protestante de Lyon, Service Gastro-entérologie, F-69300 Caluire et Cuire, FranceCentre Hospitalier Emile Roux, Service Oncologie, F-43000 Le Puy-en-Velay, FranceCentre Hospitalier Emile Roux, Service Oncologie, F-43000 Le Puy-en-Velay, FranceCentre Hospitalier de Béziers, Service Gastro-entérologie, F-34500 Béziers, FranceCentre Hospitalier Saint-Joseph Saint-Luc, Service Hépato-gastro-entérologie, F-69007 Lyon, FranceCentre Hospitalier Alpes Leman, Service Gastro entérologie, F-74130 Contamine sur Arve, FranceCentre hospitalier Intercommunal Les Hôpitaux du Léman, Service Gastro-entérologie, F-74203 Thonon les bains, FranceCentre Hospitalier de Vichy, Service Chirurgie digestive et viscérale, F-03200 Vichy, FranceGroupe Hospitalier Mutualiste de Grenoble, Service Oncologie, F-38000 Grenoble, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, F-63000 Clermont-Ferrand, FranceCHU Clermont-Ferrand, Service Pharmacie, Clermont-Ferrand, F-63000 Clermont-Ferrand, FranceCHU Clermont-Ferrand, Service Pharmacie, Clermont-Ferrand, F-63000 Clermont-Ferrand, FranceService de Chirurgie digestive, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France(1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal cancer. (2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess the prevalence of CIPN, as well as its consequences (neuropathic pain, anxiety, depression, and quality of life) in cancer survivors during the 5 years after the end of adjuvant oxaliplatin chemotherapy. (3) Results: Out of 406 patients, the prevalence of CIPN was 31.3% (95% confidence interval: 26.8–36.0). Little improvement in CIPN was found over the 5 years, and 36.5% of patients with CIPN also had neuropathic pain. CIPN was associated with anxiety, depression, and deterioration of quality of life. None of the patients with CIPN were treated with duloxetine (recommendation from American Society of Clinical Oncology), and only 3.2%, 1.6%, and 1.6% were treated with pregabalin, gabapentin, and amitriptyline, respectively. (4) Conclusions: Five years after the end of chemotherapy, a quarter of patients suffered from CIPN. The present study showed marked psychological distress and uncovered a failure in management in these patients.https://www.mdpi.com/2077-0383/9/8/2400peripheral neuropathyoxaliplatincolorectal cancerhealth-related quality of lifecancer survivors |
| spellingShingle | Marie Selvy Bruno Pereira Nicolas Kerckhove Coralie Gonneau Gabrielle Feydel Caroline Pétorin Agnès Vimal-Baguet Sergey Melnikov Sharif Kullab Mohamed Hebbar Olivier Bouché Florian Slimano Vincent Bourgeois Valérie Lebrun-Ly Frédéric Thuillier Thibault Mazard David Tavan Kheir Eddine Benmammar Brigitte Monange Mohamed Ramdani Denis Péré-Vergé Floriane Huet-Penz Ahmed Bedjaoui Florent Genty Cécile Leyronnas Jérôme Busserolles Sophie Trevis Vincent Pinon Denis Pezet David Balayssac Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study Journal of Clinical Medicine peripheral neuropathy oxaliplatin colorectal cancer health-related quality of life cancer survivors |
| title | Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study |
| title_full | Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study |
| title_fullStr | Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study |
| title_full_unstemmed | Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study |
| title_short | Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study |
| title_sort | long term prevalence of sensory chemotherapy induced peripheral neuropathy for 5 years after adjuvant folfox chemotherapy to treat colorectal cancer a multicenter cross sectional study |
| topic | peripheral neuropathy oxaliplatin colorectal cancer health-related quality of life cancer survivors |
| url | https://www.mdpi.com/2077-0383/9/8/2400 |
| work_keys_str_mv | AT marieselvy longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT brunopereira longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT nicolaskerckhove longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT coraliegonneau longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT gabriellefeydel longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT carolinepetorin longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT agnesvimalbaguet longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT sergeymelnikov longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT sharifkullab longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT mohamedhebbar longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT olivierbouche longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT florianslimano longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT vincentbourgeois longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT valerielebrunly longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT fredericthuillier longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT thibaultmazard longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT davidtavan longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT kheireddinebenmammar longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT brigittemonange longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT mohamedramdani longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT denispereverge longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT florianehuetpenz longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT ahmedbedjaoui longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT florentgenty longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT cecileleyronnas longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT jeromebusserolles longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT sophietrevis longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT vincentpinon longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT denispezet longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy AT davidbalayssac longtermprevalenceofsensorychemotherapyinducedperipheralneuropathyfor5yearsafteradjuvantfolfoxchemotherapytotreatcolorectalcanceramulticentercrosssectionalstudy |